Athersys, Inc.

Athersys, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Athersys, Inc. is not a good growth stock. Athersys, Inc. is not very popular among insiders. Athersys, Inc. is a mediocre stock to choose.

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance...

News

Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

Zolmax Investment analysts at StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX Get Free Report) in a research note issued on Thursday. The brokerage set a hold rating on...\n more…

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

Business Wire Athersys, Inc. (Nasdaq: ATHX), (Athersys or the Company) a cell therapy and regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announces it has entered...\n more…

StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

Ticker Report StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical...\n more…

Athersys crashes after bankruptcy warning

Seeking Alpha - Healthcare Athersys crashes after bankruptcy warning...\n more…

Athersys inches closer to bankruptcy as stroke cell therapy fails interim analysis

FierceBiotech.com - Biotech Athersys inches closer to bankruptcy as stroke cell therapy fails interim analysis\naarmstrong\nTue, 10/10/2023 - 10:16...\n more…

Athersys trading resumes

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…